Avibactam

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Avibactam
Avibactam structure 2.svg
Avibactam ball-and-stick model.png
Systematic (IUPAC) name
(1R,2S,5R)-2-Carbamoyl-5-methyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate
Clinical data
Trade names Avycaz (formulated with ceftazidime)
Legal status
Routes of
administration
intravenous
Pharmacokinetic data
Bioavailability 100% (intravenous)
Protein binding 5.7–8.2%[1]
Metabolism nil
Onset of action increases in proportion to dose
Excretion Renal (97%)
Identifiers
CAS Registry Number 1192500-31-4
ATC code J01
PubChem CID: 9835049
ChemSpider 8010770
ChEBI CHEBI:85984 YesY
ChEMBL CHEMBL1689063
Chemical data
Formula C7H11N3O6S
Molecular mass 265.24 g/mol

Avibactam is a non-β-lactam β-lactamase inhibitor antibiotic being developed by Actavis jointly with AstraZeneca. A new drug application for avibactam in combination with ceftazidime was approved by the FDA on February 25, 2015, for treating complicated urinary tract and complicated intra-abdominal Infections caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant gram-negative bacterial pathogens.[2][3][4]

Increasing resistance to cephalosporins among Gram-(-) bacterial pathogens, especially among hospital-acquired infections, results in part from the production of beta lactamase enzymes that deactivate these antibiotics. While the co-administration of a beta lactamase inhibitor can restore antibacterial activity to the cephalorsporin, previously approved beta lactamase inhibitors such as tazobactam and Clavulanic acid do not inhibit important classes of beta lactamase including Klebsiella pneumoniae carbapenemases (KPCs), metallo-beta lactamases, and AmpC. Avibactam inhibits KPCs, AmpC, and some Class D beta lactamases, but is not active aganist NDM-1.[5]

References[edit]

  1. ^ "Full Prescribing Information: AVYCAZ™ (ceftazidime-avibactam) for Injection, for intravenous use". ©2015 Actavis. All rights reserved. Retrieved 1 June 2015. 
  2. ^ Zhanel, GG (2013). "Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination". Drugs 73 (2): 159-77. doi:10.1007/s40265-013-0013-7. PMID 23371303. 
  3. ^ "Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product". Actavis—a global, integrated specialty pharmaceutical company—Actavis. Actavis plc. Retrieved 1 June 2015. 
  4. ^ Ehmann, DE; Jahic, H; Ross, PL; Gu, RF; Hu, J; Durand-Réville, TF; Lahiri, S; Thresher, J; Livchak, S; Gao, N; Palmer, T; Walkup, GK; Fisher, SL (2013). "Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases". The Journal of biological chemistry 288 (39): 27960–71. doi:10.1074/jbc.M113.485979. PMC 3784710. PMID 23913691. 
  5. ^ "www.accessdata.fda.gov" (PDF). 

External links[edit]